首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

2075136

口服生技藥品市場：依藥物類別、疾病適應症、通路及地區分類

Oral Biologics Market, By Drug Class, By Disease Indication, By Distribution channel, By Geography

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，口服生物製藥市場規模將達到65.2億美元，2033年將達到549.8億美元。預計從2026年到2033年，該市場將以35.6%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	65.2億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	35.60%	2033年市場規模預測：	549.8億美元

生物製藥是指生物來源的治療產品。生物製藥廣泛用於治療多種疾病，包括糖尿病、斑塊型乾癬、關節炎、克隆氏症和潰瘍性大腸炎。

口服生物製藥是指用於治療口腔疾病的生物製藥。目前，大多數生物製藥都是透過腸外途徑給藥，市面上唯一核准的口服生物製藥是鳥苷酸環化酶C促效劑。

然而，市場上的主要參與者正在努力開發口服類升糖素肽-1 (GLP-1) 受體促效劑、重組酶、生長抑制素類似物和各種激素，以用於一系列適應症。

市場動態

大型企業擴大採用非內生性成長策略，例如聯盟、夥伴關係、併購等，這是市場成長的關鍵促進因素。例如，2021年2月，百康生物製藥有限公司宣布與國際糖尿病聯盟（IDF）合併，後者是胰島素生物相似藥公司。此次合併旨在集中精力發展百康生物製藥部門的研發，並使百康的胰島素產品惠及全球糖尿病患者。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數對全球口服生技藥品市場的主要參與者進行了分析：公司概況、財務表現、產品系列、市場地位、分銷策略、主要發展、策略和未來計劃。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
這份《全球口服生物製藥市場報告》旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用全球口服生物製藥市場分析中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

公司簡介
- Novo Nordisk A/S
- Biocon Limited
- Oramed Pharmaceuticals, Inc.
- Rani Therapeutics
- Entera Bio Ltd.
- AbbVie Inc.
- Enteris BioPharma, Inc.
- Chiasma, Inc.
- Allena Pharmaceuticals, Inc.

第9章

參考
調查方法

簡介目錄

Product Code: CMI989

Oral Biologics Market is estimated to be valued at USD 6.52 Bn in 2026 and is expected to reach USD 54.98 Bn by 2033, growing at a compound annual growth rate (CAGR) of 35.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 6.52 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	35.60%	2033 Value Projection:	USD 54.98 Bn

Biological drugs refer to therapeutic products derived from living organisms or contain components of living organisms. Biological drugs are widely used in the treatment of number of diseases including diabetes, plaque psoriasis, arthritis, Crohn's disease, and ulcerative colitis.

Oral biologics products refer to the biological drugs taken from oral disease indication. Currently, majority of biological drugs are administrated by parenteral route and only guanylate cyclase-c agonist class of drug is approved oral biologics in market.

However, key players in the market are involved in development of orally administered glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, and various hormone for different indications.

Market Dynamics

Increasing number of inorganic strategies such as collaborations, partnerships, mergers, and acquisition by key players is a major factor driving growth of the market. For instance, in February 2021, Biocon Limited announced merger with International Diabetes Federation (IDF), an insulin biosimilar company, and the merger focuses on the research and development of Biocon's biologics segment and promote the affordable access of insulin products manufactured by Biocon to the diabetes patients globally.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global oral biologics market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharma, Inc., Chiasma, Inc. and Allena Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global oral biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oral biologics market

Detailed Segmentation:

Global Oral Biologics Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
Hormone
Recombinant Enzyme
Guanylate Cyclase-C Agonist
Somatostatin Analogue
Others
Global Oral Biologics Market, By Disease Indication (Revenue, USD Bn, 2021 - 2033)
Diabetes
Hyperoxaluria
Acromegaly
Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
Global Oral Biologics Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Oral Biologics Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- By Drug Class
  - Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  - Hormone
  - Recombinant Enzyme
  - Guanylate Cyclase-C Agonist
  - Somatostatin Analogue
  - Others
- By Disease Indication
  - Diabetes
  - Hyperoxaluria
  - Acromegaly
  - Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  - Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - U.S.
  - Canada
Latin America
- By Drug Class
  - Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  - Hormone
  - Recombinant Enzyme
  - Guanylate Cyclase-C Agonist
  - Somatostatin Analogue
  - Others
- By Disease Indication
  - Diabetes
  - Hyperoxaluria
  - Acromegaly
  - Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  - Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Drug Class
  - Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  - Hormone
  - Recombinant Enzyme
  - Guanylate Cyclase-C Agonist
  - Somatostatin Analogue
  - Others
- By Disease Indication
  - Diabetes
  - Hyperoxaluria
  - Acromegaly
  - Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  - Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Drug Class
  - Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  - Hormone
  - Recombinant Enzyme
  - Guanylate Cyclase-C Agonist
  - Somatostatin Analogue
  - Others
- By Disease Indication
  - Diabetes
  - Hyperoxaluria
  - Acromegaly
  - Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  - Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Drug Class
  - Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  - Hormone
  - Recombinant Enzyme
  - Guanylate Cyclase-C Agonist
  - Somatostatin Analogue
  - Others
- By Disease Indication
  - Diabetes
  - Hyperoxaluria
  - Acromegaly
  - Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  - Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Drug Class
  - Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  - Hormone
  - Recombinant Enzyme
  - Guanylate Cyclase-C Agonist
  - Somatostatin Analogue
  - Others
- By Disease Indication
  - Diabetes
  - Hyperoxaluria
  - Acromegaly
  - Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  - Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- By Distribution Channel
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Novo Nordisk A/S *
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Biocon Limited
Oramed Pharmaceuticals, Inc.
Rani Therapeutics
Entera Bio Ltd.
AbbVie Inc.
Enteris BioPharma, Inc.
Chiasma, Inc.
Allena Pharmaceuticals, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Oral Biologics Market, By Drug Class, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Hormone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Recombinant Enzyme
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Guanylate Cyclase-C Agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Somatostatin Analogue
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

5. Global Oral Biologics Market, By Disease Indication, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Hyperoxaluria
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Acromegaly
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

6. Global Oral Biologics Market, By Distribution Channel, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

7. Global Oral Biologics Market, By Region, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2021 - 2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Novo Nordisk A/S
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Biocon Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Oramed Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Rani Therapeutics
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Entera Bio Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AbbVie Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Enteris BioPharma, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Chiasma, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Allena Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies